Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pharmacokinetics and drug/drug interaction of cetuximab and
repeated PK measurements week 1-13
No
Christoph Zielinski, MD
Principal Investigator
Dept of Internal Medicine, Medical University Vienna
Austria: Federal Ministry for Health and Women
CETRA 01
NCT00367250
July 2006
June 2011
Name | Location |
---|